Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
- Klimek, Ludger
- Jutel, Marek
- Akdis, Cezmi
- Bousquet, Jean
- Akdis, Mübeccel
- Bachert, Claus
- Agache, Ioana
- Ansotegui, Ignacio
- Bedbrook, Anna
- Bosnic-Anticevich, Sinthia
- Canonica, Giorgio W
- Chivato, Tomas
- Cruz, Alvaro A
- Czarlewski, Wiencyslawa
- Giacco, Stefano Del
- Du, Hui
- Fonseca, Joao A
- Gao, Yadong
- Haahtela, Tari
- Hoffmann-Sommergruber, Karin
- Ivancevich, Juan-Carlos
- Iaccarino, Guido
- Khaltaev, Nikolai
- Knol, Edward F
- Kuna, Piotr
- Larenas-Linnemann, Desiree
- Melen, Erik
- Mullol, Joaquim
- Naclerio, Robert
- Ohta, Ken
- Okamoto, Yoshitaka
- O'Mahony, Liam
- Onorato, Gabrielle L
- Papadopoulos, Nikos G
- Pawankar, Ruby
- Pfaar, Oliver
- Samolinski, Boleslaw
- Schwarze, Jurgen
- Toppila-Salmi, Sanna
- Shamji, Mohamed H
- Ventura, Maria Teresa
- Valiulis, Arunas
- Yorgancioglu, Arzu
- Matricardi, Paolo
- Zuberbier, Torsten
Publication date
January 2020
DOIAbstract
The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient
Add to ORKG